Dr. Jonathan Trent on FDA Approval of Trabectedin for Soft Tissue Sarcomas
Dr. Jonathan Trent discusses the FDA approval of trabectedin for patients with soft tissue sarcomas.
Jonathan C. Trent, MD, professor of Medicine, co-director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the FDA approval of trabectedin for patients with soft tissue sarcomas.
Trabectedin was approved in the United States after a promising phase III study that consisted of 518 patients who had previously been treated with anthracycline. Trabectedin was approved for use in patients with soft tissue sarcoma, including liposarcoma and leiomyosarcoma subtypes, on October 23, 2015.
Radical Prostatectomy Shows Less Genitourinary Toxicity in Localized Prostate Cancer
April 30th 2025A study of 47,387 patients found radical prostatectomy had the lowest long-term risk of severe genitourinary complications after localized prostate cancer treatment compared to combination therapies.
Read More
